Group items matching

in title, tags, annotations or url

Global consumer healthcare company Haleon has launched a new centre of excellence for a global leader in consumer health which will bring together world leading academics in human behaviour and frontline healthcare professionals including community pharmacists. Unveiled at the International Pharmaceutical Federation (FIP) Congress in 'sunny' Seville, Spain on September 20, the Centre will operate as a community of healthcare professionals and specialists in behavioural science, health psychology and the social sciences to solve some of the most pressing everyday health challenges. Named the Centre for Human Sciences (CHS) the initiative will be the first major programme for healthcare professionals since the Haleon's launch on July 18 as an independent, global leader in consumer health. The Centre's mission is to support practising health professionals - pharmacists, pharmacy assistants and dental professionals - in serving their patients and communities. Combining science with deep human understanding, CHS will bring expertise in physiology together with human sciences to deliver real world-solutions and tangible interventions, resulting in measurable improvements in health outcomes through sustained behavioural change. The Centre is facilitated by Robert Horne, professor of Behavioural Medicine at UCL School of Pharmacy, who started his career as a practising pharmacist but later chose to become a behavioural scientist when he saw an opportunity to address issues around psycho-social factors that acted as a hindrance in pharmacy practice. Speaking to me in an exclusive three-way conversation alongside Tess Player, the global head of healthcare professional & health influencer marketing at Haleon, on the sidelines of the FIP Congress 2022, Prof Horne expanded on what the Centre was all about and how it would work. "We've got some good ideas, but it's not a pre-filled prescription that we're going to deliver at scale from the start. What Haleon is t

Amgen Inc sued Novartis AG's Sandoz in a federal court in the United States on Monday (May 1), accusing Sandoz's proposed versions of its multibillion-dollar bone-strengthening drugs Prolia and Xgeva of infringing several patents. Amgen asked the New Jersey court to block Sandoz's biosimilars of the drugs until its patents expire. One of the patents named in the complaint does not expire until 2037. Sandoz declined to comment on the lawsuit on Tuesday. Novartis, which is also named in the complaint, is preparing to spin Sandoz off into a standalone company later this year. Amgen's Prolia is used to treat osteoporosis. Xgeva, with the same active ingredient denosumab, treats bone cancer and prevents fractures in bone-cancer patients.

An alliance of companies has pledged to ensure equitable access to vaccines and treatments for pandemics, as the friction around intellectual property rights for Covid-19 interventions between the pharmaceutical industry and developing nations endures. At the heart of the plan is a commitment to set aside part of the production of vaccines and treatments upfront for vulnerable populations in low-income countries when the next pandemic arises, given how fragmented access to Covid tools has left many populations unprotected. In order to do better next time - and without knowing which companies will develop the first drugs and vaccines for the next pandemic - having the industry collectively make this commitment is potentially transformative, said Thomas Cueni, head of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA). The pledge, called the Berlin Declaration, was made on July 19 by members of the global pharmaceutical industry group that include many of the companies involved in developing Covid interventions, such as AstraZeneca, GSK, Moderna, Pfizer and Merck. The declaration is not legally binding. However, if a company that signed on reneges on its vow, it would face grave consequences in the court of public opinion, said Cueni.

The Federation of Small Businesses (FSB) on Thursday (4 December) announced a new strategic partnership with the Bank of England to protect small businesses from the risks associated with accepting counterfeit banknotes. Cash is still the number one customer payment method for 25 per cent of small high street businesses, and cash payments are expected to increase during the festive period, according to FSB. By becoming a Strategic Partner of the Bank of England's Banknote Checking Scheme, the organisation is trying to help its members become aware of the use of counterfeit notes, which has reputational and financial impacts. The FSB is encouraging its members to sign up to the Scheme, which offers training materials to staff so they can identify a counterfeit note at point of sale and know what to do with it, as well as stay up to date with best practice and bank note developments.

It has been reported that several Austrians have been taken to the hospital after injecting fake Ozempic, as confirmed by health regulator. Austria's Federal Office for Safety in Health Care (BASG) confirmed that the patients have suffered hypoglycaemia and seizures. It is believed that the injections contained insulin instead of the weight loss drug, semaglutide. The health regulator has urged doctors and patients to verify their medication stocks.

The University friends purchased the North London pharmacy for a confidential sum. Nabeel Patel, a GP pharmacist at Haringey GP Federation and Huseyin Akpinar, a former councillor at Enfield Council bought it following a confidential sales process with Mark Page at Christie & Co. Kiran and Nita Patel, who have owned and operated Beautychem Pharmacy since 1989, have decided to retire. They claimed that the pharmacy had "dispensed an average of 6,576 items per month". Kiran Patel, former owner of Beautychem Pharmacy, said: "It's been a pleasure serving the Tottenham community over the last 34 years. Over the years, we've seen many changes in the pharmacy profession, but the constant has been the customers and the respect they have for what each independent pharmacy does for them.

The International Pharmaceutical Federation (FIP) launched a report on pharmacy-led common ailment schemes. The data was collected from 24 countries, including case studies from nine countries. It highlighted the growing demand for care models for ageing populations and the increase in chronic non-communicable diseases. Pharmacists had been managing the stress, including prescribing authority and provision of medicinal treatments. Paul Sinclair AM, Global President of FIP, said, "I believe this report is both a foundation and a catalyst - a foundation on which FIP and our member organizations could base initial strategies and a catalyst to drive us to seek even more diverse and comprehensive insights in the future.

Pharmacists globally are broadening their roles to support self-care, aiming to enhance patient health outcomes through increased contributions and proactive behaviours, according to a new report. However, significant barriers, including inadequate funding and limited access to patient records, impede the optimisation of self-care activities and outcomes improvement in this area, the International Pharmaceutical Federation (FIP) said in its report. The FIP report, titled 'Community Pharmacy Insights: Supporting the Need for Self-Care,' gathers insights from 238 respondents across 55 countries with the aim of providing evidence-based policy support for workforce development. Nearly all respondents (93.2 per cent) indicated that pharmacists should actively engage in providing self-care support, FIP said. Furthermore, 48.9 per cent supported the involvement of pharmacy technicians, while 39.2 per cent endorsed the participation of pharmacy assistants and other team members in offering self-care support.

The Royal Pharmaceutical Society (RPS) has re-joined the International Pharmaceutical Federation (FIP) after reflecting its commitment to international collaboration and the advancement of the pharmacy profession. RPS President Professor Claire Anderson said: "Members told us they wanted to see us re-join FIP to further our commitment to international partnerships which support education and advocacy to develop and progress the pharmacy profession.". "We fully recognise the importance of international collaboration and the sharing of knowledge and best practice with our peers across the world. "FIP are refocusing their membership offer and we're delighted to work with them on opportunities for professional development and increased visibility and recognition for the pharmacy profession." Paul Bennett, RPS CEO said: "Now that we have re-joined, our teams across RPS look forward to reinvigorating the close collaboration we have previously enjoyed with our colleagues both within FIP itself, and across the breadth of FIP Member organisations to further our vision and mission".

The Pharmacists' Defence Association (PDA) said it has supported the application of the Royal Pharmaceutical Society (RPS) to rejoin the International Pharmaceutical Federation (FIP), the global body representing the interests of pharmacy. Under FIP rules, if a new application from an additional organisation from the same country applies to join, the existing members in that country are consulted about that decision and are asked for their approval before FIP council members determine if the application is accepted. The PDA joined FIP earlier this year, and RPS, which has decided not to renew FIP membership at the end of last year, has now submitted a fresh application to join. RPS decision to leave, taken after a vote, has invited much criticism. The organisation, a founding member, had attributed high membership fees and associated costs for leaving FIP While the PDA has confirmed that it would not oppose the membership application of the RPS, it has asked FIP to find a suitable method to ascertain a transparent declaration of membership numbers from the RPS in the event of FIP Council deciding to admit RPS.

In 2024, cannabis users will get more protection from their employers when it comes to smoking outside of work. In the meantime, here's a refresher on who can use weed - and when and where - in California. Can my employer penalize me for cannabis use? California recently passed a new cannabis bill, protecting employees from weed bias, but it will be a while before it goes into effect. Called AB 2188, it bans employers from discriminating against employees based on their use of weed off the job and away from the workplace. This includes the hiring, employment and termination processes. The law's exceptions include people working in the construction and building industry or positions that require federal background clearances. And while it protects off-duty smoking, employers will still have the right to fire or suspend employees for using weed or being high while at work. Although the bill was signed by Gov. Gavin Newsom in September, it won't be carried out until January 2024. Weed might be legal, but not for everyone Recreational cannabis use has been legal since 2016, but only for those 21 years old and over. Those under 18 who are caught with weed will be subject to drug education or counseling and community service. People who are older than 18 but under 21, will be fined up to $100. But minors can apply for a medical marijuana identification card to get weed for medicinal purposes. In California, children under 18 years old can apply as a patient if they are emancipated or have declared self-sufficiency status, according to the state's Department of Health. If they do not have this status, then the county will contact the individual's parent or legal guardian. The legal limit of weed How much cannabis you can have on hand is limited in California, according to the state's health and safety code. You'll be penalized if you possess more than 28.5 grams of weed, or more than eight grams of concentrated cannabis - essentially about one

"Raise awareness of pharmacies as places of primary health care provision," advocates the International Pharmaceutical Federation (FIP), emphasising the need for universal recognition of pharmacists as essential healthcare professionals. Despite significant advancements in pharmacy practice, many policymakers and members of the public still view pharmacies primarily as commercial enterprises rather than essential providers of healthcare services. The FIP is leading a campaign to change this perception, advocating for pharmacies to be recognised as vital components of primary health care. Primary health care is crucial for achieving "health for all." In 2018, the Declaration of Astana saw governments recommit to strengthening primary health care to achieve universal health coverage. FIP, a signatory to this declaration, has since been dedicated to enhancing the role and impact of pharmacies in primary health care.

The US Doctors and citizens are still waiting for the results of state and federal investigations at the New England Compounding Center of Framingham.

The program's overall goal is to give practices the motivation, support, and infrastructure needed to deliver coordinated, high-quality care within the current work environment. Initially, the Blueprint model was pilot tested in three areas and now serves more than half the state's residents in 14 communities. Early trends in the pilot communities suggest that the program has reduced utilization and growth in health care spending and improved the provision of appropriate care and services.

Federal health officials say they found listeria throughout the packing facility of the Colorado farm whose cantaloupe have so far caused 25 deaths and more than 125 illnesses.

In wake of last year's BP oil spill in the Gulf of Mexico, a new study from an environmental watchdog group contends that current federal standards underestimate the risk to pregnant women and children of cancer-causing contaminants that can accumulate in seafood from such spills.